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ABSTRACT
Objectives: To measure the incidence of Bell’s palsy
and determine the impact of clinical trial findings on
Bell’s palsy management in the UK.
Design: Interrupted time series regression analysis
and incidence measures.
Setting: General practices in the UK contributing to
the Clinical Practice Research Datalink (CPRD).
Participants: Patients ≥16 years with a diagnosis of
Bell’s palsy between 2001 and 2012.
Interventions: (1) Publication of the 2004 Cochrane
reviews of clinical trials on corticosteroids and
antivirals for Bell’s palsy, which made no clear
recommendation on their use and (2) publication of
the 2007 Scottish Bell’s Palsy Study (SBPS), which
made a clear recommendation that treatment with
prednisolone alone improves chances for complete
recovery.
Main outcome measures: Incidence of Bell’s palsy
per 100 000 person-years. Changes in the
management of Bell’s palsy with either prednisolone
therapy, antiviral therapy, combination therapy
(prednisolone with antiviral therapy) or untreated
cases.
Results: During the 12-year period, 14 460 cases of
Bell’s palsy were identified with an overall incidence of
37.7/100 000 person-years. The 2004 Cochrane
reviews were associated with immediate falls in
prednisolone therapy (−6.3% (−11.0 to −1.6)), rising
trends in combination therapy (1.1% per quarter (0.5
to 1.7)) and falling trends for untreated cases (−0.8%
per quarter (−1.4 to −0.3)). SBPS was associated with
immediate increases in prednisolone therapy (5.1%
(0.9 to 9.3)) and rising trends in prednisolone therapy
(0.7% per quarter (0.4 to 1.2)); falling trends in
combination therapy (−1.7% per quarter (−2.2 to
−1.3)); and rising trends for untreated cases (1.2% per
quarter (0.8 to 1.6)). Despite improvements, 44% still
remain untreated.
Conclusions: SBPS was clearly associated with
change in management, but a significant proportion of
patients failed to receive effective treatment, which
cannot be fully explained. Clarity and uncertainty in
clinical trial recommendations may change clinical
practice. However, better ways are needed to
understand and circumvent barriers in implementing
clinical trial findings.
INTRODUCTION
The foundations of medical evidence are
based on ﬁndings from clinical trials but
their translation into clinical practice is an
uncertain process and can be problematic.1–3
The Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial
(ALLHAT), which demonstrated an
increased risk of cardiovascular events with
doxazosin compared to chlorthalidone, was
associated with modest but limited reduc-
tions in α-blocker prescribing in the USA,
ARTICLE SUMMARY
Article focus
▪ What is the incidence of Bell’s palsy in people
aged 16 years onwards in the UK?
▪ What has been the impact of clinical trial find-
ings on the management of Bell’s palsy?
Key messages
▪ The incidence of Bell’s palsy is 37.7/100 000
person-years, higher than previously thought.
▪ Clinical trial findings were clearly associated with
change in management.
▪ A significant proportion of Bell’s palsy cases still
appear to be untreated.
Strengths and limitations of this study
▪ This is the largest population-based study evalu-
ating Bell’s palsy incidence and management.
▪ The dataset used is of high quality and validated
for use in research.
▪ Interrupted time series regression assesses
association rather than causation.
▪ The reasons for the high proportion of untreated
cases remain largely unknown.
Morales DR, Donnan PT, Daly F, et al. BMJ Open 2013;3:e003121. doi:10.1136/bmjopen-2013-003121 1
Open Access Research
 o
n
 17 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2013-003121 on 16 July 2013. Downloaded from 
but there was no immediate impact in other countries.4 5
Several theoretical and practical barriers to achieve
knowledge translation exist in implementation research
and it has been suggested that multifaceted approaches
tailored to the intervention under review are superior to
passive dissemination.6 Two studies assessing the impact
of implementing the UK National Institute for Clinical
Excellence (NICE) guidelines reported variable results
suggesting that factors including professional experi-
ence, a stable evidence base and cost implications may
all inﬂuence the clinician’s behaviour.7 8 Similar results
from a range of clinical settings have been found in
other countries.9–11
Large population-based studies measuring the inci-
dence of Bell’s palsy (acute idiopathic facial palsy) are
rare. The currently published incidence rates of Bell’s
palsy are inconsistent, varying from as low as 11/100 000
to 51.9/100 000 person-years.12–18 A part of this variation
is related to heterogeneity in the method of case detec-
tion and differences in diagnostic criteria used. In add-
ition, not all published studies are large population-based
studies and variations in sampling techniques may bias
measures of disease occurrence. The incidence of Bell’s
palsy in the UK has been reported only once at 20.2/
100 000 person-years.18 However, this measure was based
on electronic health data at a time when electronic
medical records (EMRs) were not as widespread or as
well integrated into clinical practice as they are now.
Currently, 97% of UK family doctors use EMRs.19
In 2007, the results of a large factorial randomised clin-
ical trial examining the effectiveness of corticosteroids
alone or in combination with antivirals for Bell’s palsy
were reported in the New England Journal of Medicine.20
The Scottish Bell’s Palsy Study (SBPS) clearly demon-
strated that early treatment with prednisolone signiﬁ-
cantly improved the chance of complete recovery and
that treatment with aciclovir conferred no additional
beneﬁt. The clinical trial received publicity from other
medical journals, evidence-based collections and the
general media, raising the proﬁle of the article and
helping to disseminate its recommendations.21 22 Prior to
SBPS, the recommendations on the effectiveness of corti-
costeroids and antivirals for Bell’s palsy were unclear.23 24
In 2009, a Cochrane review of clinical trials for antivirals
in Bell’s palsy was published, incorporating both SBPS
and data from a large Swedish clinical trial reporting
similar ﬁndings.25 26 The need for high-quality research
in this area was therefore demonstrated; large robust clin-
ical trials were conducted, clear recommendations were
made and the results were widely disseminated. In this
regard, it would be reasonable to assume changes in clin-
ical practice, would then follow. Use of EMRs provides a
valuable opportunity to evaluate the impact of clinical
trials at a population level and provide robust measures
of occurrence. We decided to evaluate the impact of clin-
ical trial data on Bell’s palsy management, which has
never been reported, and determine the incidence of
Bell’s palsy over a 12-year period.
METHODS
The study was conducted using data from the Clinical
Practice Research Datalink (CPRD) in the UK, formerly
known as the General Practice Research Database.27
CPRD is one of the world’s largest longitudinal data-
bases containing EMRs from over 640 UK general prac-
tices. CPRD contains electronic data about patient
demographics, prescriptions, clinical events, medical
diagnoses, hospital referrals, admissions and deaths.
Medical diagnoses and clinical events are recorded
using the Read code system of classiﬁcation.28 General
practices are required to meet deﬁned quality standards
in order to contribute data to CPRD, which is of high
quality having been validated for use in research.29 30
Study population
The study population consisted of all patients ≥16 years
of age with an incident diagnosis of Bell’s palsy occur-
ring between 1 January 2001 and 30 September 2012.
New Bell’s palsy cases were deﬁned by an incident Read
code for Bell’s palsy in patients with an up-to-standard
medical history of at least 1 year before the incident
Read code for Bell's palsy (F310). The incidence rates
for Bell’s palsy were calculated per year and for the
overall study period. The numerator was the total
number of new Bell’s palsy cases recorded by general
practitioners and the denominator was the number of
person-years of total population from contributing prac-
tices. Rates per 100 000 person-years were calculated by
gender directly standardised to the European standard
population.
Outcome
For each new Bell’s palsy case, prescription data were
used to deﬁne four different treatment categories con-
sisting of oral prednisolone therapy, oral antiviral
therapy, oral prednisolone with antiviral (combined)
therapy and untreated cases. Treatments were deﬁned
by prescriptions occurring within 7 days before and after
the date of diagnosis. Antiviral therapy was deﬁned by
prescriptions for oral acyclovir, famciclovir or valaciclovir.
The proportion of patients treated for Bell’s palsy was
measured per quarter stratiﬁed by treatment category.
The denominator used was the total number of new
Bell’s palsy cases per quarter. Quarters were deﬁned
from the beginning of January 2001 ( January, February
and March) to the end of the third-quarter of 2012. For
ease of reference, quarters are labelled 2001q1–2012q3.
Referral to secondary care was determined by the pres-
ence of a referral code in the primary care records
occurring within 14 days of the date of diagnosis for spe-
cialties of the ear, nose and throat (ENT), ophthalmol-
ogy and neurology. Referral codes were based on the
National Health Service (NHS) classiﬁcation. Owing to
the limited number of referrals, the proportion of Bell’s
palsy cases referred to secondary care was measured per
year.
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Events
Events were prespeciﬁed according to the publication of
the 2004 Cochrane systematic reviews of clinical trials,
which made no clear recommendation on the use of
corticosteroids and antivirals for Bell’s palsy
(2004q2)23 24 and SBPS, which made clear recommen-
dations that treatment with prednisolone alone
improved chances of complete recovery (2007q3).20
Statistical analysis
Interrupted time series for the speciﬁed outcomes were
plotted and the impact was examined in a single-
segmented regression analysis model with parameters
for the two events.31 Key parameters for each event were
estimated: (1) the slope or trend in treatment before
the event, (2) the step change in treatment immediately
following the event and (3) the change in trend from
the pre-event trend. The presence of serial autocorrel-
ation was tested for using the Durbin-Watson statistic
with visual inspection of residuals plots. The minimum
number of data points between interventions was 13.
Associations between untreated cases and the patient
characteristics of age and gender were evaluated using
multivariate binary logistic regression. Analysis was con-
ducted using PASW Statistics V.18 (IBM Software 2009)
and STATAV.11 (StataCorp, 2009).
RESULTS
Incidence of Bell’s palsy
A total of 14 460 patients with incident Bell’s palsy were
identiﬁed (table 1). The overall incidence of Bell’s palsy
for the study period was 37.7/100 000 person-years. The
incidence of Bell’s palsy increased with age and was
similar for gender. The annual standardised incidence
of Bell’s palsy remained fairly constant throughout the
period of study (ﬁgure 1).
Effect of clinical trials on management
Time trends for the management of Bell’s palsy are
shown in ﬁgure 2. In 2001q1, Bell’s palsy was treated
with prednisolone only in 33.4% (95% CI 29.8 to 37.0),
combined therapy in 5.1% (95% CI 1.7 to 8.5), antivirals
only in 1.1% (95% CI −0.1 to 2.3) and was untreated in
60.4% (95% CI 57.1 to 63.8). The baseline trend was ﬂat
for all treatment categories, that is, there were no
signiﬁcant quarter-to-quarter changes in treatment
(table 2). The 2004 Cochrane systematic reviews of clin-
ical trials were associated with a signiﬁcant absolute step
fall in treatment with prednisolone −6.3% (95% CI
−11.0 to −1.6) during 2004q2 without any signiﬁcant
change in trend, change from a ﬂat to a signiﬁcantly
rising trend in treatment with combined therapy of
1.1% per quarter (95% CI 0.5 to 1.7) and change from
a ﬂat to a signiﬁcantly falling trend in untreated patients
(−0.8% per quarter (95% CI −1.4 to −0.3)).
SBPS was associated with a signiﬁcant immediate step
rise in treatment with prednisolone only of 5.1% (95%
CI 0.9 to 9.3) followed by a rising trend of 0.7% per
quarter (95% CI 0.4 to 1.2), change from a rising to a
falling trend in treatment with combined therapy of
−1.7% per quarter (95% CI −2.2 to −1.3), change from
a falling to a rising trend in untreated patients (1.2%
per quarter (95% CI 0.8 to 1.6)) and change to a falling
trend in treatment with antivirals alone (−0.2% per
quarter (95%CI −0.4 to −0.0)).
Untreated cases
The proportion of untreated patients with Bell’s palsy
fell from a baseline of 60% during the 12-year study
period but remained at 44% at 2012q3. The proportion
of untreated patients with Bell’s palsy was high across all
Table 1 Incidence of Bell’s palsy (per 100 000 person-years) by age and gender
Age (years)
Male Female
Overall incidenceN (%) Incidence* N (%) Incidence
16–29 949 (46.2) 24.0 1107 (53.8) 30.3 27.0
30–39 1155 (49.2) 33.6 1194 (50.8) 35.6 34.5
40–49 1313 (52.2) 34.4 1202 (47.8) 32.5 33.4
50–59 1341 (52.0) 40.0 1237 (48.0) 37.6 38.8
60–69 1229 (51.0) 45.9 1180 (49.0) 42.9 44.4
≥70 1154 (45.2) 66.6 1399 (54.8) 68.2 67.4
Figure 1 Image showing the incidence of Bell’s palsy in the
UK (per 100 000 person-years) from 2001 to 2012, standardised
to the European standard population. Error bars, 95% CIs.
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age categories (range 44.4–58%, table 3) but was signiﬁ-
cantly greater in patients over the age of 60 years. The
probability of being untreated was not signiﬁcantly inﬂu-
enced by gender.
Referrals to secondary care
Of the 14 460 new Bell’s palsy cases identiﬁed, a total of
1051 (7.3%, 95% CI 6.9 to 7.7) patients were referred to
ENT, ophthalmology or neurology. More treated cases of
Bell’s palsy were referred to secondary care than
untreated cases (9.2% (95% CI 8.5 to 9.9) for treated vs
6.5% (95% CI 5.9 to 7.1) for untreated). The propor-
tion of patients referred to secondary care fell during
the study period (ﬁgure 3), ranging from 9.2% (95% CI
7.5 to 11.2) in the ﬁrst quarter of 2001 to 5.9% (95% CI
4.6 to 7.6) in the third quarter of 2012 (difference 3.3%,
95% CI −0.1 to 6.6%).
DISCUSSION
Clinical trial ﬁndings are the cornerstone of medical evi-
dence to judge the effectiveness of interventions, but
not all recommendations effectively translate into clin-
ical practice. Evaluating changes in prescribing behav-
iour at a population level can support clinical trials in
measuring their impact.
Impact of clinical trial evidence
SBPS was associated with a signiﬁcant clinical impact on
Bell’s palsy management by increasing treatment with
corticosteroids and reducing combination therapy with
antivirals based on the results of time series regression
analysis. Use of prednisolone alone increased by 70%
from the point immediately before publication of SBPS
to the highest point in 2010. Conversely, combination
therapy fell by 41% from the point immediately before
publication of SBPS to the lowest point in 2010. Equally
important, however, uncertainty in recommendation or
lack of evidence from clinical trials also appears to sig-
niﬁcantly inﬂuence clinical practice. This is highlighted
by the 2004 reviews, which were associated with an
increase in combination therapy by 323% from the
lowest point in 2004 to the highest point in 2007. There
are several reasons why this may have occurred. Clinical
uncertainties regarding effectiveness may have justiﬁed
the use of antivirals with increasing pharmaceutical pro-
motion. This would also indirectly promote corticoster-
oid use and help explain the falling trend in untreated
patients. When no evidence for antivirals was found, pro-
motion of combination therapy for Bell’s palsy may have
stopped, thus halting the falling trend in untreated
patients. Corticosteroids being off-patent cheap drugs
were unlikely to be marketed in the same way.
Uncertainty in clinical management partly stems from
uncertainty regarding aetiology. If a non-viral aetiology
for Bell’s palsy was conﬁrmed, the use of antiviral
therapy would be biologically implausible. Further work
could usefully address the aetiology of Bell’s palsy.
Adoption of clinical trial ﬁndings from SBPS clearly
occurred but was limited despite clear recommendations
and subsequent dissemination. In this regard, a signiﬁ-
cant number of patients are still treated with antivirals
and even more appear to receive no effective treatment
despite updated recommendations.26 32 In addition,
there is a suggestion that the rising trend in
prednisolone-only therapy and the falling trend in com-
bination therapy over the past year of observation is plat-
eauing, which may be an effect related to the time since
publication. This may be related to the conﬂicting recom-
mendations for antiviral use appearing in the literature
Figure 2 Image showing the
management of Bell’s palsy in the
UK according to treatment.
Reference line 1 shows the 2004
Cochrane systematic reviews for
Bell’s palsy. Reference line 2
shows the 2007 Scottish Bell’s
Palsy Study (SBPS).
4 Morales DR, Donnan PT, Daly F, et al. BMJ Open 2013;3:e003121. doi:10.1136/bmjopen-2013-003121
Incidence and management of Bell’s palsy in the UK 2001–2012
 o
n
 17 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2013-003121 on 16 July 2013. Downloaded from 
after SBPS, especially in relation to severe cases.33–35
These uncertainties make recommendations less likely to
be adopted.10 Relatively few studies have attempted to
evaluate the impact of clinical trials on clinical practice.
The ALLHAT trial was a large randomised double-blind
trial in which the study doxazosin arm was terminated
early due to an unfavourable risk of cardiovascular events
compared to treatment with chlorthalidone. The
ALLHAT trial was associated with a 26% reduction in
annual α-blocker prescription orders, a 22% reduction in
dispensed α-blocker prescriptions and a 54% reduction
in physician-reported α-blocker drug use in the USA.4
Despite the clinically signiﬁcant reductions, signiﬁcant
numbers of patients with hypertension still received treat-
ment with α-blockade and it was proposed that further
strategies are required to increase the impact that clinical
trial ﬁndings should have. Our study observed similar
ﬁndings in that, although a clinically signiﬁcant impact
occurred, clinical evidence was not fully adopted.
Untreated cases
Signiﬁcant numbers of patients failed to receive effective
therapy for Bell’s palsy. Increasing age is associated with
increasing comorbidity, which may lead to relative
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Table 3 Untreated cases according to age and gender
with results from multivariate logistic regression analysis
Variable Untreated (%) OR (95%CI) p Value
Age groups
16–29 913 (44.4) –
30–39 1105 (47.0) 1.11 (0.99 to 1.25) 0.077
40–49 1157 (46.0) 1.07 (0.95 to 1.20) 0.263
50–59 1225 (47.6) 1.14 (1.01 to 1.28) 0.032
60–69 1215 (50.4) 1.28 (1.13 to 1.44) <0.001
>70 1480 (58.0) 1.73 (1.54 to 1.94) <0.001
Gender
Male 3459 (48.4) –
Female 3636 (49.7) 1.04 (0.98 to 1.11) 0.231
Figure 3 Image showing the trends in referral to secondary
care for Bell’s palsy in the UK from 2001 to 2012.
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contraindications to therapy. Although older patients had
the greatest probability of being untreated, the propor-
tion of untreated patients was high among all age cat-
egories with 44.4% of patients under the age of 30 years
appearing to not receive any effective treatment by the
end of the study period. It is therefore likely that the rela-
tive contraindications to therapy as a result of comorbid-
ities would account for only a minority of untreated cases.
In older patients, the main differential diagnosis of Bell’s
palsy is stroke, which may have resulted in more patients
receiving investigation and treatment from secondary
care services. In this regard, cases may have presented to
accident and emergency rather than primary care as a
result of recommendations for rapid urgent assessment
of suspected stroke, potentially overestimating the
number of untreated patients in this age category.
Conversely, concerns regarding a diagnosis of stroke may
also lead to delayed diagnosis of Bell’s palsy, potentially
missing the opportunity for early effective treatment with
prednisolone therapy in these patients.
Incidence
The incidence of Bell’s palsy was similar between
genders, increased with age and remained fairly con-
stant throughout the 12-year period. The incidence of
Bell’s palsy varies markedly throughout the literature
with differences partly relating to the method of case
detection or diagnostic criteria used. Although the inci-
dence of Bell’s palsy in this study was greater than for
others,14 15 17 18 a large US study using electronic health
surveillance data reported a similar incidence of 42.7/
100 000 person-years.16 Our study also reported similar
increases in incidence with age found elsewhere.16 18
Given the low rate of referrals to ENT, ophthalmology
and neurology specialties (the main specialties patients
with Bell’s palsy would be referred to in the UK), it sug-
gests that primary care physicians diagnose and treat the
great majority of cases. For the UK at least, primary care
data are therefore a valuable source for measuring the
incidence of Bell’s palsy. Only one other study has
reported incidence rates from the UK. Rowlands et al18
used EMRs from 1992 to 1996 to estimate an incidence of
20/100 000 person-years, a ﬁgure signiﬁcantly lower than
ours. It remains uncertain whether the incidence of
Bell’s palsy has truly increased or simply been measured
more accurately. The previous study used data at a time
when EMRs and established coding practices were not as
widespread or as well integrated into clinical practice as
they are now, which may have led to an under-recording
of cases. The fairly stable trend in incidence over a
12-year period from our study also makes it less likely that
the incidence of Bell’s palsy has increased over time.
Strengths and limitations
This is the largest population-based study evaluating the
incidence and management of Bell’s palsy in adults.
Bell’s palsy may occur rarely in children; however, the
vast majority of cases will occur in adults and increases
substantially with age. Acute idiopathic facial palsy in
children is more likely to be managed in secondary care,
from which no prescribing data are available. As such,
the inclusion of patients assessing the impact of clinical
trial data would be to underestimate the impact of clin-
ical trial ﬁndings. Perhaps of greater importance lies in
demonstrating the impact of clinical trials on Bell’s palsy
management, which has never been reported potentially
having wider implications. Cochrane systematic reviews
are considered a gold standard for summaries of
evidence-based healthcare in the UK and internationally,
because of the rigorous approach in combining high-
standard medical research. For this reason, the
Cochrane systematic reviews of clinical trials were evalu-
ated, especially as changes in recommendation occurred
during the study period. In the UK, patients register
with general practices in order to access free healthcare
from NHS. Most prescriptions, including those recom-
mended from secondary care, are issued electronically
from general practice making UK EMRs a valuable tool
for research. Bell’s palsy cases were diagnosed by family
physicians in real-life settings and no scale was used to
quantify the degree of facial nerve dysfunction. We are
unable to ascertain whether or not the diagnosis of
Bell’s palsy was recorded at initial presentation or follow-
ing complete investigation. For this reason, we included
prescriptions issued within a 7-day period before and
after the date of Bell’s palsy recording. Some patients
may have received treatment from other sources (eg,
accident and emergency units) with potential overesti-
mation of untreated patients. However, this is likely to be
a minority of patients due to the culture of healthcare
provision in the UK and the size and quality of the data-
base used. Although it would appear from the low rate
of referrals to ophthalmology, ENT and neurology that
Bell’s palsy is primarily managed in primary care, we
cannot exclude the possibility that patients were referred
to other disciplines, potentially underestimating the
number of referrals. Time series regression assesses asso-
ciation rather than causation, but remains a strong
design for estimating the effects of interventions in non-
randomised settings.29 Despite this, we cannot exclude
the possibility that other events may have occurred
which inﬂuenced the ﬁndings.
Clinical implications
A large proportion of patients do not appear to receive
any effective treatment for their condition. Although the
majority of Bell’s palsy cases will resolve spontaneously,
full recovery is more likely and quicker in those treated
with prednisolone.20 36 This is important as around 30%
of untreated patients will suffer long-term problems,
including facial disﬁgurement potentially complicated
by facial contracture, reduced sense of taste, speech pro-
blems, eye–mouth synkinesias, corneal ulceration and
adverse psychological impact. Clearly, any treatment
which reduces the risk of long-term complications and
speeds up recovery should be considered. Therefore,
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more people should be offered early treatment with cor-
ticosteroids for Bell’s palsy. More broadly, there is a soci-
etal need in healthcare research to better evaluate the
impact of large clinical trials and not to assume that
knowledge translation occurs naturally via passive dis-
semination. More work is therefore needed to under-
stand and circumvent the barriers to adoption of clinical
trial evidence. In conclusion, clinical trial ﬁndings had a
clear impact on primary care management of Bell’s
palsy, but a signiﬁcant proportion of patients failed to
receive effective treatment. Clinical trials making clear
recommendations could be associated with changes to
clinical practice, but their impact may still be limited.
Conversely, lack of evidence or uncertain clinical trial
recommendations may also be associated with changes
in clinical practice. Better ways are needed to circum-
vent the barriers to implementing clinical trial results.
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